Predictive Modeling of Drug Response in Non-Hodgkin’s Lymphoma-Reference-Cited by-同舟云学术

Predictive Modeling of Drug Response in Non-Hodgkin’s Lymphoma

Published:2015-06-10 Issue:6 Volume:10 Page:e0129433
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Frieboes Hermann B.,Smith Bryan R.,Wang Zhihui,Kotsuma Masakatsu,Ito Ken,Day Armin,Cahill Benjamin,Flinders Colin,Mumenthaler Shannon M.,Mallick Parag,Simbawa Eman,AL-Fhaid A. S.,Mahmoud S. R.,Gambhir Sanjiv S.,Cristini Vittorio

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference50 articles.

1. Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies;OA O'Connor;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2009

2. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study;OA O'Connor;Journal of clinical oncology: official journal of the American Society of Clinical Oncology,2011

3. Phase I study of BCX1777 (forodesine) in patients with relapsed or refractory peripheral T/natural killer-cell malignancies;M Ogura;Cancer science,2012

4. New drugs for the treatment of lymphoma;L Paoluzzi;Hematology/oncology clinics of North America,2008

5. The schedule-dependent effects of the novel antifolate pralatrexate and gemcitabine are superior to methotrexate and cytarabine in models of human non-Hodgkin's lymphoma;LE Toner;Clinical cancer research: an official journal of the American Association for Cancer Research,2006

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Computational Approaches for Multiscale Modeling;Encyclopedia of Cell Biology;2023

2. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling;ELIFE;2021

3. Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling;eLife;2021-11-09

4. Evaluation of solid tumor response to sequential treatment cycles via a new computational hybrid approach;Scientific Reports;2021-11-02

5. Conversion of RNA Aptamer into Modified DNA Aptamers Provides for Prolonged Stability and Enhanced Antitumor Activity;Journal of the American Chemical Society;2021-05-14